RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

NCT01149356 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

NIH

Sponsor class

Stopped Manufacturer discontinued drug development.

Conditions

Estrogen Receptor Positive
HER2/Neu Negative
Male Breast Carcinoma
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: Exemestane
DRUG: Gamma-Secretase Inhibitor RO4929097
DRUG: Goserelin Acetate

Sponsor

National Cancer Institute (NCI)